Copyright ©The Author(s) 2015.
World J Hepatol. Feb 27, 2015; 7(2): 213-225
Published online Feb 27, 2015. doi: 10.4254/wjh.v7.i2.213
Figure 1
Figure 1 Management of hepatitis C virus in patients with renal disease and kidney transplantation. Empiric dose changes should be done in conjunction with therapeutic drug monitoring. BOC: Boceprevir; TVR: Telaprevir; SMV: Simeprevir; SFV: Sofosbuvir; CYP3A4: Cytochrome P450 3A4; mTOR: Mammalian target of rapamycin; MMF: Mycophenolate mofetil.
Figure 2
Figure 2 Proposed pathogenesis of hepatitis C virus-related immunogenic and lymphoproliferative disorders. HCV: Hepatitis C virus; NOS: Nitric oxide synthase; ROS: Reactive oxygen species; AID: Activation-induced deaminase.